Pieris Pharmaceuticals, Inc. (PVLA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Pieris Pharmaceuticals (PVLA) is accelerating the development of immunotherapy through synthesis robotization and AI-driven molecular design. The development of Anticalin proteins for pulmonology is being monetized via strategic alliances with pharmaceutical behemoths. A compact staff of biologists expands only for specific clinical projects. The EV/EBITDA dynamics reflect the issuer's current maturity phase, where 0.00 determines this parameter level.
pieris.com - analytical breakdowns and key metrics (PVLA)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Pieris Pharmaceuticals|PVLA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Pieris Pharmaceuticals, Inc.|PVLA - Company Cumulative Debt|Debt to Book Capitalization Ratio Pieris Corp|PVLA - Long-Term Liabilities|Company Short-Term Debts Pieris Pharmaceuticals|Quick Ratio pieris.com
- business earnings and investment ratios data:
PVLA - Company Net Income|Expected Profit Pieris Pharmaceuticals|PVLA - Company Value to Net Income|Forward P/E Multiple Pieris Pharmaceuticals|PVLA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Corp|PVLA - Operating income before deduction of amortization|Net earnings per share for the last 12 months Pieris Pharmaceuticals|PVLA - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months pieris.com|PVLA - Earnings per share trend in current year|Earnings growth forecast for next year Pieris Pharmaceuticals
Initial company analysis:PVLA (Pieris Pharmaceuticals Inc)
Minimizing investment risks requires analyzing business value relative to its operating profit before depreciation and debt. For Pieris Pharmaceuticals (PVLA), whose capitalization depends on Anticalin patent protection and deals with big pharma behemoths, the company's historical EV/EBITDA chart reflects the real value of its assets. This indicator allows for an assessment of business overpayment, taking into account debt load and tax obligations.
Direct competitors
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio DNTH|PHVS: EV/EBITDA Multiple|ABCL - Total Company Value to Operating Income Before Depreciation Ratio|TRML (Tourmaline Bio) - EV/EBITDA Multiple|Company Value to EBITDA Precigen Inc PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming (PHAR)|NKTR (Nektar Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple UPB (Upstream Bio Inc)|Total Company Value to Operating Income Before Depreciation Ratio zenasbio.com (ZBIO)|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Gossamer Bio Inc GOSS|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Septerna Pharma - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Savara Inc.|rigel.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ANAB|ATXS (Astria Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ENGN (enGene Bio)|EV/EBITDA Multiple rapt.com RAPT|JBIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ACRS (aclaristx.com)|Kyverna Therapeutics, Inc. (KYTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Tiziana Life Sciences Ltd.|CABA (Cabaletta Bio, Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple Ventyx Biosciences, Inc|EV/EBITDA Multiple THTX|Enterprise Value to EBITDA Ratio avalotx.com AVTX|EV/EBITDA Multiple ELDN (Eledon Pharmaceuticals, Inc.)|Agenus, Inc. (AGEN) - Company Value to EBITDA|CLYM: Enterprise Value to EBITDA Ratio|ZURA - EV/EBITDA Multiple|ATYR (aTyr Pharma, Inc.) - Enterprise Value to EBITDA Ratio|ADAG: Enterprise Value to Operating Income Before Depreciation Ratio|IMA (ImageneBio) - EV/EBITDA Multiple|Shattuck Therapeutics (STTK) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EQ|Enterprise Value to EBITDA Ratio connectbiopharm.com CNTB|EV/EBITDA Multiple IMUX (Immunic)|EV/EBITDA Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XFOR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|adicetbio.com (ACET) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CELU - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio, Inc.|barinthusbio.com - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio KZR (Kezar Life Sciences, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SABS (SAB Biotherapeutics Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akari Therapeutics plc AKTX|Enlivex Therapeutics Ltd - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Q32 Bio Corp - EV/EBITDA Multiple|GOVX - EV/EBITDA Multiple|Edesa Biotech (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio IBIO (iBio Inc)|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|XTLB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLT|EV/EBITDA Multiple hcwbiologics.com (HCWB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc. APVO|Business Value to Operating Income Before Depreciation AIM|ADTX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRI Bio Corporation (GRI) - Enterprise Value to EBITDA Ratio|XRTX: EV/EBITDA Multiple|reshapelifesciences.com (HIND) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio REVB|INDP: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SCNI|Total Company Value to Operating Income Before Depreciation Ratio calcimedica.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGM Biosciences, Inc. (IGMS) - Enterprise Value to EBITDA Ratio|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to Operating Income Before Depreciation THRD (thirdharmonicbio.com)
